Abstract
(Lancet. 2022;400:1743–1745) Pregnant and postpartum women have an increased risk for venous thromboembolism (VTE) (0 to 1%) with a history of VTE increasing the likelihood (2% to 10%). Hypercoagulability, endothelial damage, and venous stasis are contributing factors. Low–molecular-weight heparin (LMWH) thromboprophylaxis during pregnancy to 6 weeks postpartum is the recommended treatment for women with history of VTE, yet evidence-based dosage recommendations are lacking, causing dosage variation between countries and practices.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
